141 related articles for article (PubMed ID: 7396451)
21. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis.
Daver NG; Shelburne SA; Atmar RL; Giordano TP; Stager CE; Reitman CA; White AC
J Infect; 2007 Jun; 54(6):539-44. PubMed ID: 17198732
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations.
Bayer AS; Lam K
J Infect Dis; 1985 Jan; 151(1):157-65. PubMed ID: 3965588
[TBL] [Abstract][Full Text] [Related]
23. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
Antimicrob Agents Chemother; 1989 Aug; 33(8):1184-7. PubMed ID: 2802547
[TBL] [Abstract][Full Text] [Related]
24. Novel Use of Rifabutin and Rifapentine to Treat Methicillin-Resistant Staphylococcus aureus in a Rat Model of Foreign Body Osteomyelitis.
Karau MJ; Schmidt-Malan SM; Albano M; Mandrekar JN; Rivera CG; Osmon DR; Oravec CP; Berry DJ; Abdel MP; Patel R
J Infect Dis; 2020 Oct; 222(9):1498-1504. PubMed ID: 32914837
[TBL] [Abstract][Full Text] [Related]
25. Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy.
Norden CW; Bryant R; Palmer D; Montgomerie JZ; Wheat J
South Med J; 1986 Aug; 79(8):947-51. PubMed ID: 3526570
[TBL] [Abstract][Full Text] [Related]
26. Causes and Implications of the Disappearance of Rifampin Resistance in a Rat Model of Methicillin-Resistant Staphylococcus aureus Foreign Body Osteomyelitis.
Brinkman CL; Tyner HL; Schmidt-Malan SM; Mandrekar JN; Patel R
Antimicrob Agents Chemother; 2015 Aug; 59(8):4481-8. PubMed ID: 25987614
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis.
Euba G; Murillo O; Fernández-Sabé N; Mascaró J; Cabo J; Pérez A; Tubau F; Verdaguer R; Gudiol F; Ariza J
Antimicrob Agents Chemother; 2009 Jun; 53(6):2672-6. PubMed ID: 19307354
[TBL] [Abstract][Full Text] [Related]
28. Clindamycin combination treatment for the treatment of bone and joint infections caused by clindamycin-susceptible, erythromycin-resistant Staphylococcus spp.
Bonnaire A; Vernet-Garnier V; Lebrun D; Bajolet O; Bonnet M; Hentzien M; Ohl X; Diallo S; Bani-Sadr F
Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115225. PubMed ID: 33099073
[TBL] [Abstract][Full Text] [Related]
29. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections.
Hoyo I; Martínez-Pastor J; Garcia-Ramiro S; Climent C; Brunet M; Cuesta M; Mensa J; Soriano A
Scand J Infect Dis; 2012 Jul; 44(7):548-50. PubMed ID: 22385321
[TBL] [Abstract][Full Text] [Related]
30. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with teicoplanin.
Norden CW; Niederreiter K; Shinners EM
Infection; 1986; 14(3):136-8. PubMed ID: 2942488
[TBL] [Abstract][Full Text] [Related]
31. Oral rifampin and trimethoprim/sulfamethoxazole therapy in asymptomatic carriers of methicillin-resistant Staphylococcus aureus infections.
Ellison RT; Judson FN; Peterson LC; Cohn DL; Ehret JM
West J Med; 1984 May; 140(5):735-40. PubMed ID: 6610253
[TBL] [Abstract][Full Text] [Related]
32. Community-acquired methicillin-resistant Staphylococcus aureus in bone and joint infections: development of rifampicin resistance.
Donaldson AD; Chan RC; Gosbell IB
Med J Aust; 2006 Feb; 184(4):196. PubMed ID: 16489910
[No Abstract] [Full Text] [Related]
33. Comparative evaluation of A-56619, A-56620, and nafcillin in the treatment of experimental Staphylococcus aureus osteomyelitis.
Mader JT; Morrison LT; Adams KR
Antimicrob Agents Chemother; 1987 Feb; 31(2):259-63. PubMed ID: 3566251
[TBL] [Abstract][Full Text] [Related]
34. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia.
Tan TQ; Mason EO; Ou CN; Kaplan SL
Antimicrob Agents Chemother; 1993 Nov; 37(11):2401-6. PubMed ID: 8285624
[TBL] [Abstract][Full Text] [Related]
35. Treatment of experimental osteomyelitis by liposomal antibiotics.
Kadry AA; Al-Suwayeh SA; Abd-Allah AR; Bayomi MA
J Antimicrob Chemother; 2004 Dec; 54(6):1103-8. PubMed ID: 15486079
[TBL] [Abstract][Full Text] [Related]
36. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
[TBL] [Abstract][Full Text] [Related]
37. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits.
Chambers HF; Kartalija M; Sande M
J Infect Dis; 1995 Apr; 171(4):897-902. PubMed ID: 7706817
[TBL] [Abstract][Full Text] [Related]
38. [Oral antibiotic treatment of chronic osteomyelitis in adults].
Javaloyas de Morlius M
Med Clin (Barc); 1996 Oct; 107(12):472-6. PubMed ID: 9036258
[No Abstract] [Full Text] [Related]
39. Recurrent methicillin-resistant Staphylococcus aureus osteomyelitis: combination antibiotic therapy with evaluation by serum bactericidal titers.
Aspinall SL; Friedland DM; Yu VL; Rihs JD; Muder RR
Ann Pharmacother; 1995; 29(7-8):694-7. PubMed ID: 8520082
[TBL] [Abstract][Full Text] [Related]
40. Serum inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus in volunteers receiving novobiocin and rifampin alone and in combination.
Standiford HC; Walsh TJ; Drusano GL; Tatem BA; Townsend RJ
Diagn Microbiol Infect Dis; 1993; 17(2):135-42. PubMed ID: 8243034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
